Intravesical epirubicin treatment following TUR in superficial bladder tumours
Imamoğlu, M.A.; Bakirtaş, H.; Yiğitbaşi, O.; Ersoy, H.; Sertçelik, A.N.
Archivos Espanoles de Urologia 54(10): 1147-1153
2001
ISSN/ISBN: 0004-0614 PMID: 11852530 Document Number: 531669
To evaluate the effectiveness and tolerability of intravesical epirubicin treatment to prevent recurrence and progression of superficial bladder tumor after TUR. 44 patients with superficial bladder tumor, 28 primary and 16 recurrent cases were given 50 mg intravesical epirubicin once a week for 8 weeks after TUR. Recurrent cases had not been treated by any intravesical agent before. Follow-up was done by cystoscopy, urine cytology and random biopsies. Local recurrence after treatment was found in 14.28% and 18.75%, and recurrence in another area was found in 21.42% and 31.25% of the primary and recurrent tumor groups respectively. Total recurrence in both groups was 40.91%. No systemic toxicity was observed and local side effects were treated symptomatically. Intravesical epirubicin after TUR for superficial bladder tumors especially for the primary ones, is a reliable method that provides effective prophylaxis with tolerable side effects.